What is being bought7 lots · detail below

Published requirement description

This is a notice of intention to make an award in respect of the NHS Genomic Medicine Service pursuant to the Most Suitable Provider (MSP) Process for the NHS Genomic Medicine Service (NHS GMS). For the avoidance of doubt, this is an intention to award notice. A notice of the confirmation of the award of each contract will be issued once they are signed. Pursuant to the NHS GMS contracts, provider are to provide the following functions:

Organisational leadership, governance and partnership arrangements;
Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);
Laboratory operating model;
Clinical function: cancer genomics;
Clinical function: rare disease;
Clinical function: population health;
Promotion of and supporting and leading where relevant science, research and / or innovation;
Transformation and Service Improvement;
People – workforce, education and training; and
Data and digital

CPV: Health services

Lots and requirements (7)Procurement structure

7 lots · no lot values published · same evaluation weights on every lot

Lot #1NHS North-West GMSAwarded North West

Pursuant to the NHS GMS contracts, providers are to provide the following functions: * Organisational leadership, governance and partnership arrangements; * Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD); * Laboratory operating model; * Clinical function: cancer genomics; * Clinical function: rare disease; * Clinical function: population health; * Promotion of and supporting and leading where relevant science, research and / or innovation; * Transformation and Service Improvement; * People – workforce, education and training; and * Data and digital The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service. The approximate lifetime value of the contract for all Lots is £5,175,000,000. The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods). Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).

Delivery: North West

Extensions: Options to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period.

85100000 Health services

Lot #2NHS North-East and Yorkshire GMSAwarded North East

Pursuant to the NHS GMS contracts, providers are to provide the following functions: * Organisational leadership, governance and partnership arrangements; * Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD); * Laboratory operating model; * Clinical function: cancer genomics; * Clinical function: rare disease; * Clinical function: population health; * Promotion of and supporting and leading where relevant science, research and / or innovation; * Transformation and Service Improvement; * People – workforce, education and training; and * Data and digital The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service. The approximate lifetime value of the contract for all Lots is £5,175,000,000. The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods). Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).

Delivery: North East

Extensions: Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period

85100000 Health services

Lot #3NHS Central and South GMSAwarded East Midlands, West Midlands

Pursuant to the NHS GMS contracts, providers are to provide the following functions: * Organisational leadership, governance and partnership arrangements; * Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD); * Laboratory operating model; * Clinical function: cancer genomics; * Clinical function: rare disease; * Clinical function: population health; * Promotion of and supporting and leading where relevant science, research and / or innovation; * Transformation and Service Improvement; * People – workforce, education and training; and * Data and digital The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service. The approximate lifetime value of the contract for all Lots is £5,175,000,000. The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods). Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).

Delivery: East Midlands, West Midlands

Extensions: Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period

85100000 Health services

Lot #4NHS East GMSAwarded East of England

Pursuant to the NHS GMS contracts, providers are to provide the following functions: * Organisational leadership, governance and partnership arrangements; * Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD); * Laboratory operating model; * Clinical function: cancer genomics; * Clinical function: rare disease; * Clinical function: population health; * Promotion of and supporting and leading where relevant science, research and / or innovation; * Transformation and Service Improvement; * People – workforce, education and training; and * Data and digital The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service. The approximate lifetime value of the contract for all Lots is £5,175,000,000. The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods). Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).

Delivery: East of England

Extensions: Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period

85100000 Health services

Lot #5NHS South-West GMSAwarded South West

Pursuant to the NHS GMS contracts, providers are to provide the following functions: * Organisational leadership, governance and partnership arrangements; * Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD); * Laboratory operating model; * Clinical function: cancer genomics; * Clinical function: rare disease; * Clinical function: population health; * Promotion of and supporting and leading where relevant science, research and / or innovation; * Transformation and Service Improvement; * People – workforce, education and training; and * Data and digital The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service. The approximate lifetime value of the contract for all Lots is £5,175,000,000. The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods). Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).

Delivery: South West

Extensions: Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period

85100000 Health services

Lot #6NHS North Thames GMSAwarded London

Pursuant to the NHS GMS contracts, providers are to provide the following functions: * Organisational leadership, governance and partnership arrangements; * Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD); * Laboratory operating model; * Clinical function: cancer genomics; * Clinical function: rare disease; * Clinical function: population health; * Promotion of and supporting and leading where relevant science, research and / or innovation; * Transformation and Service Improvement; * People – workforce, education and training; and * Data and digital The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service. The approximate lifetime value of the contract for all Lots is £5,175,000,000. The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods). Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).

Delivery: London

Extensions: Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period

85100000 Health services

Lot #7NHS South-East GMSAwarded South East

Pursuant to the NHS GMS contracts, providers are to provide the following functions: * Organisational leadership, governance and partnership arrangements; * Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD); * Laboratory operating model; * Clinical function: cancer genomics; * Clinical function: rare disease; * Clinical function: population health; * Promotion of and supporting and leading where relevant science, research and / or innovation; * Transformation and Service Improvement; * People – workforce, education and training; and * Data and digital The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service. The approximate lifetime value of the contract for all Lots is £5,175,000,000. The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods). Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).

Delivery: South East

Extensions: Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period

85100000 Health services

Procedure terms & legal framework

From the official record · publisher note attached

Procedure method: Award procedure without prior publication of a call for competition
Legal basis: CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
Procurement category: Services
Notice status: Awarded without competition
Procurement threshold: Unspecified in notice
Regulatory regime: Standard
Commercial structure: Stand-alone contract (no framework)
Competition type: Direct award (no call for competition)
GPA / WTO covered: Unspecified in notice
Recurring procurement: Unspecified in notice
First published: 24 Jul 2025, 17:52 BST
Last source update: 23 Oct 2025, 17:00 BST
Authority reference: C368833
FTS notice number: 2025/S 000-067976
Classification (CPV): Health services
Delivery area: North East (UKC)North West (UKD)East Midlands (UKF)West Midlands (UKG)East of England (UKH)London (UKI)South East (UKJ)South West (UKK)
Official registry OCID: ocds-h6vhtk-0565e9 Find a Tender

Why no open competition: The procurement falls outside the scope of application of the directive
Published justification: This is a Provider Selection Regime (PSR) intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Procurement Act Regulations 2023 do not apply to this award. The standstill period begins on the day after the publication of this notice. Representations by providers must be made to decision makers by Tuesday 4th November 2025. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR.

Publisher note: This is a Provider Selection Regime (PSR) intention to award notice. This intention to award notice is subject to Regulation 10(7) of the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Procurement Act Regulations 2023 do not apply to this award. The standstill period begins on the day after the publication of this notice. Representations by providers must be made to the relevant authority by midnight on Tuesday 4th November 2025. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR. Written representations should be sent to [email protected], ensuring the following details are referenced: Project reference: C368833 Project title: NHS Genomic Medicine Service - Most Suitable Provider process This decision has been made as per NHS England governance processes, by the Commercial Executive Group on 14th October 2025 and the National Commissioning Group on 21st October 2025. No conflicts of Interest were identified amongst decision-makers. Each of the 5 key criteria were balanced with equal priority and considered on this basis and consideration was given to the basic selection criteria. Following provider assessments, it was agreed that the providers are the only providers capable of meeting the service specifications and requirements of the NHS GMS in full. Additional CPV codes include: 85145000-7 (Services provided by medical laboratories), 85148000-8 (Medical analysis services) 85111810-1 (Blood analysis services) 85121200-5 (Medical specialist services) 85140000-2 (Miscellaneous health services)

How it was run

Official notice

Run through: portal not identified

Tender documents are also served through a separate tool: https://health-family.force.com/s/Welcome ↗

Submission deadline: —

Commercial outcome & contract awards

Published awards, contracts and bid statistics, not a forecast

Awards 7

Awarded value Not summedeach provider’s award repeats the list or panel total

Bids received 21

Contracts signed 7latest 21 Oct 2025

Awarded to	Value	Date	Status
Lot 1 · NHS North-West GMS1 award
Manchester University NHS Foundation Trust	£5,175,000,000 †very large published value · not counted until verified, check the notice	—	Awarded
Lot 2 · NHS North-East and Yorkshire GMS1 award
The Newcastle upon Tyne Hospitals NHS Foundation Trust	£5,175,000,000 †very large published value · not counted until verified, check the notice	—	Awarded
Lot 3 · NHS Central and South GMS1 award
Birmingham Women’s and Children’s NHS Foundation TrustLot 3 NHS Central and South GMS	£5,175,000,000 †very large published value · not counted until verified, check the notice	—	Awarded
Lot 4 · NHS East GMS1 award
CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUSTLot 4 NHS East GMS	£5,175,000,000 †very large published value · not counted until verified, check the notice	—	Awarded
Lot 5 · NHS South-West GMS1 award
NORTH BRISTOL NHS TRUSTLot 5 NHS South-West GMS	£5,175,000,000 †very large published value · not counted until verified, check the notice	—	Awarded
Lot 6 · NHS North Thames GMS1 award
Great Ormond Street Hospital for Children NHS Foundation TrustLot 6 NHS North Thames GMS	£5,175,000,000 †very large published value · not counted until verified, check the notice	—	Awarded
Lot 7 · NHS South-East GMS1 award
Guy's and St Thomas' NHS Foundation TrustLot 7 NHS South-East GMS	£5,175,000,000 †very large published value · not counted until verified, check the notice	—	Awarded

Contracts

Lot 1 - NHS North-West GMS · Manchester University NHS Foundation Trust
Signed
21 Oct 2025
Value
£5,175,000,000
Status
active
Lot 2 - NHS North-East and Yorkshire GMS · The Newcastle upon Tyne Hospitals NHS Foundation Trust
Signed
21 Oct 2025
Value
£5,175,000,000
Status
active
Lot 3 NHS Central and South GMS · Birmingham Women’s and Children’s NHS Foundation Trust
Signed
21 Oct 2025
Value
£5,175,000,000
Status
active
Lot 4 NHS East GMS · CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST
Signed
21 Oct 2025
Value
£5,175,000,000
Status
active
Lot 5 NHS South-West GMS · NORTH BRISTOL NHS TRUST
Signed
21 Oct 2025
Value
£5,175,000,000
Status
active
Lot 6 NHS North Thames GMS · Great Ormond Street Hospital for Children NHS Foundation Trust
Signed
21 Oct 2025
Value
£5,175,000,000
Status
active
Lot 7 NHS South-East GMS · Guy's and St Thomas' NHS Foundation Trust
Signed
21 Oct 2025
Value
£5,175,000,000
Status
active

Bid statistics published by the authority

Lot	Bids	SME	VCSE	Valid bid range
1 · NHS North-West GMS	3bids	—	—	—
2 · NHS North-East and Yorkshire GMS	3bids	—	—	—
3 · NHS Central and South GMS	3bids	—	—	—
4 · NHS East GMS	3bids	—	—	—
5 · NHS South-West GMS	3bids	—	—	—
6 · NHS North Thames GMS	3bids	—	—	—
7 · NHS South-East GMS	3bids	—	—	—

Contracting authority & participating public bodies

NHS England

Contracting authorityCentral GovernmentBody governed by public lawHealth 7&8 Wellington Place, Leeds, Yorkshire & Humber, LS1 4APContact name, email

Dispute resolution & review bodies

NHS Arden and Greater East Midlands Commissioning Support UnitReview body Derby

Bidders & participating suppliers

7 commercial parties on the notice

Birmingham Women’s and Children’s NHS Foundation TrustAwarded supplier Birmingham, West Midlands
Cambridge University Hospitals NHS Foundation TrustAwarded supplier Cambridge, East of England
Great Ormond Street Hospital for Children NHS Foundation TrustAwarded supplier London, London
Guy's and St Thomas' NHS Foundation TrustAwarded supplier London, London
Manchester University NHS Foundation TrustAwarded supplier Manchester, North West
North Bristol NHS TrustAwarded supplier Bristol, South West
The Newcastle upon Tyne Hospitals NHS Foundation TrustAwarded supplier Newcastle, North East

Official documents & specifications

Official links; attachments are not copied

No document links were published on the notice.

NHS Genomic Medicine Service - Most Suitable Provider Process

What is being bought7 lots · detail below

Lots and requirements (7)Procurement structure

Procedure terms & legal framework

How it was run

Timeline

Notice history

Commercial outcome & contract awards

Contracting authority & participating public bodies

Bidders & participating suppliers

Official documents & specifications